|
1
|
Buruli ulcer disease in Cameroon rediscovered.
|
Am J Trop Med Hyg
|
2004
|
2.29
|
|
2
|
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
|
Lancet Infect Dis
|
2013
|
1.68
|
|
3
|
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
|
Antivir Ther
|
2005
|
1.30
|
|
4
|
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
|
AIDS Res Hum Retroviruses
|
2008
|
1.19
|
|
5
|
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
|
J Acquir Immune Defic Syndr
|
2008
|
1.14
|
|
6
|
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
|
Antivir Ther
|
2009
|
1.03
|
|
7
|
Sexually transmitted infections among female sex workers in Kupang, Indonesia: searching for a screening algorithm to detect cervical gonococcal and chlamydial infections.
|
Sex Transm Dis
|
2003
|
1.02
|
|
8
|
Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
|
AIDS
|
2007
|
1.01
|
|
9
|
Women experience a better long-term immune recovery and a better survival on HAART in Lao People's Democratic Republic.
|
BMC Infect Dis
|
2013
|
0.99
|
|
10
|
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
|
BMC Public Health
|
2010
|
0.89
|
|
11
|
Do patents prevent access to drugs for HIV in developing countries?
|
JAMA
|
2002
|
0.78
|